IntrinsicIntrinsic
OverviewFinancialsChartBusiness SummaryFilingsOwnershipValuation

TECHPRECISION CORP (TPCS)

Business Summary

TechPrecision Corporation operates as a manufacturer of precision, large-scale fabricated and machined metal structural components and systems, serving customers in two main industry groups: defense and precision industrial. The company's operations and customers are entirely within the United States, and it focuses on the defense industry to reliably pivot with defense customers to jointly develop manufacturing capabilities. The company does not design the products it manufactures but rather produces according to "build-to-print" requirements specified by customers, and it does not manufacture products in anticipation of orders.

The company faces competition from both domestic and foreign entities in the manufacture of metal-fabricated and machined precision components and equipment, with the industry being fragmented with no one dominant player. Competitors include companies both larger and smaller than TechPrecision, some of which may be better known, have greater resources, or have lower production costs. The company believes customers focus on quality of work, reputation, ability to meet schedule, and price, and that its strengths in these areas allow it to compete effectively as one of a select group of companies that can provide its products and services. The company's ten largest customers generated 92% of total revenue in fiscal 2026 and 96% in fiscal 2025, with the largest single customer in fiscal 2026 and fiscal 2025 being a prime defense contractor accounting for 15% and 22% of revenue, respectively.

TechPrecision generates revenue through custom manufacturing services, transforming raw materials into precision finished products for customers primarily in the defense and aerospace markets, and secondarily in precision industrial sectors. Revenue is recognized over time based on the transfer of control of promised goods or services, or at a point in time, with the majority of contracts having a single performance obligation. The company does not own intellectual property rights to any proprietary marketed product and does not manufacture in anticipation of orders, with manufacturing operations commencing only after receiving a customer's purchase order. Contracts are generated through negotiation with customers and from bids pursuant to requests for proposal.

The company operates through two wholly owned subsidiaries, each a reportable segment: Ranor and Stadco. Ranor's manufacturing operations are situated on approximately 65 acres in Westminster, Massachusetts, leveraging 145,000 square foot facilities to provide custom solutions including manufacturing engineering, materials management, high-precision heavy fabrication, heavy high-precision machining, QC inspection, NonDestructive Testing, and final packaging. Ranor is an ISO 9001:2015 certificate holder, is registered and compliant with ITAR, and has over 95% of its revenue in the defense sector. Stadco's manufacturing operations are situated in an industrial multi-building complex of approximately 183,000 square feet under roof in Los Angeles, California, manufacturing large mission-critical components for military aircraft, military helicopter, and military space programs, as well as tooling, molds, fixtures, jigs, and dies. Stadco is an AS 9100 D and ISO 9001:2015 certificate holder, a NADCAP NonDestructive Testing certificate holder, is registered and compliant with ITAR, and has almost all of its revenue in the defense sector. Stadco features a large electron beam welding cell and two NonDestructive Testing work cells as a unique mission-critical technology set.

In fiscal 2026, Ranor generated revenue of $16,946 and Stadco generated revenue of $15,306 , with intersegment elimination of $608 resulting in consolidated revenue of $31,644 . Ranor's gross profit was $6,324 and Stadco's gross profit was negative $1,349 , leading to consolidated gross profit of $4,975 . Ranor's operating income was $3,772 , Stadco's operating loss was $4,137 , and corporate and unallocated operating loss was $702 , resulting in a consolidated operating loss of $1,067 . The company's backlog of orders totaled $52,198 as of March 31, 2026, compared to $48,625 as of March 31, 2025.

During fiscal 2026, the company determined it was not in compliance with certain financial covenants in its Loan Agreement as of March 31, 2026, and management believes it is probable the company will not be in compliance in future periods. The lender under the Loan Agreement agreed to extend the maturity date of the revolver loan to September 15, 2026 . The company acknowledged that a certain event of default has occurred and is continuing under the Loan Agreement due to failure to satisfy the Leverage Ratio as of March 31, 2026. The company also identified material weaknesses in internal control over financial reporting pertaining to initial purchase accounting and continuing fair value accounting associated with the Stadco acquisition, insufficient complement of Stadco accounting staff, accounting for impairment of long-lived assets, and segregation of duties. The company incurred no expenses for research and development in fiscal 2026 and fiscal 2025.

For the fiscal year ended March 31, 2026, consolidated revenue was $31,644 , a decrease of $2,387 or 7% compared to $34,031 in fiscal 2025. Consolidated gross profit increased by $646 or 15% to $4,975 , with gross margin expanding to 16% from 13% in the prior year. The company reported an operating loss of $1,067 compared to an operating loss of $2,158 in fiscal 2025, an improvement of $1,091 or 51%. Net loss was $2,218 for fiscal 2026 compared to a net loss of $2,676 in fiscal 2025, with basic and diluted loss per share of $0.22 in fiscal 2026 versus $0.27 in fiscal 2025.

Business Outlook & Financial Sufficiency

The company's primary growth vector is its focus on the defense industry, with approximately 99% of revenue in both fiscal 2026 and fiscal 2025 derived from customers in the defense sector. The company targets repeating custom programs with relatively mature and stable designs to provide long-term solutions for customers, and its backlog of $52,198 as of March 31, 2026 is expected to be delivered over the next two to three fiscal years. The company manufactures components for U.S. Navy submarines and aircraft carriers, USMC military helicopters, and defense and aerospace programs, including the Virginia-class fast attack submarine program and the Columbia-class ballistic missile submarine program.

The company's second growth vector involves broadening its customer base and the industries it serves, though it remains primarily focused on defense. The company markets to its existing customer base and initiates contacts with new potential customers through personal contacts, customer referrals, and referrals from other businesses. The company's backlog at Ranor was $29,405 as of March 31, 2026, and Stadco's backlog was $22,793 as of the same date, with new orders continuing to flow from existing customers for components related to military aircraft, military helicopter, and military space programs.

The company's gross margin expanded to 16% in fiscal 2026 from 13% in fiscal 2025, driven by a favorable project mix at Ranor where gross profit increased by $650 or 11% on a 12% decrease in cost of revenue. At Stadco, gross profit remained negative at $1,349 as the segment continues to work through unfavorable legacy contracts and first article parts, though repairs and maintenance costs decreased by 28% in fiscal 2026. Consolidated SG&A expenses decreased by $445 or 7% to $6,042 in fiscal 2026, driven by decreases in professional fees and office costs.

The company's operational outlook focuses on improving manufacturing capacity utilization at its Stadco subsidiary and improving the manufacturing process to increase revenue recognition over time and improve job performance. The company plans to closely monitor expenses and, if required, reduce operating costs and capital spending to enhance liquidity. The company's manufacturing operations are partly dependent on the availability of raw materials, with most contracts requiring customer-supplied raw materials, and the company endeavors to establish alternate sources of material supply to reduce dependency on any one supplier.

The company's capital allocation strategy is constrained by its debt agreements, which restrict the ability to declare or pay dividends. The company has never paid dividends on its common stock and does not anticipate paying dividends in the foreseeable future. The company incurred no expenses for research and development in fiscal 2026 and fiscal 2025. The company's Loan Agreement with the Bank includes a revolving line of credit with a maximum principal amount of $4,500 , and as of March 31, 2026, there was $7,031 outstanding under the Loan Agreement.

A significant headwind is the company's substantial doubt about its ability to continue as a going concern, as its auditors have indicated. The company's liquidity is highly dependent on the availability of financing facilities and its ability to maintain a gross profit and operating income. The company was not in compliance with certain financial covenants in the Loan Agreement as of March 31, 2026, and management believes it is probable the company will not be in compliance in future periods. Without a waiver, noncompliance permits the lender to demand repayment in full of all outstanding amounts, and the company does not have existing facilities or sufficient cash on hand to satisfy these obligations.

Another constraint is the company's dependence on a limited number of customers, with its four largest customers accounting for 52% of revenue in fiscal 2026 and its five largest customers accounting for 79% of revenue in fiscal 2025. The company's backlog as of March 31, 2026 and 2025 was $52,198 and $48,625 , respectively, of which 75% and 73% was attributable to four customers. The company also faces risks from reductions in defense spending, as approximately 99% of revenue in both fiscal 2026 and 2025 was derived from the defense industry, and changes in U.S. government programs or requirements could materially harm business prospects.

Management Sentiments & Priorities

Management's message emphasizes the company's focus on the defense industry and its two reportable segments, Ranor and Stadco, each manufacturing precision components primarily for defense customers. The company's strategic priorities include improving manufacturing capacity utilization at Stadco, enhancing the manufacturing process to increase revenue recognition over time, and closely monitoring expenses to enhance liquidity. Management acknowledges substantial doubt about the company's ability to continue as a going concern due to noncompliance with financial covenants in the Loan Agreement and the uncertainty of obtaining waivers or additional financing. The company's backlog of $52,198 as of March 31, 2026 is expected to be delivered over the next two to three fiscal years, and management believes the company's reputation for technical expertise, attention to detail, and commitment to quality allows it to compete effectively.

Financial Details

For the fiscal year ended March 31, 2026, total consolidated revenue was $31,644 , compared to $34,031 in fiscal 2025, a decrease of $2,387 or 7%. Net loss was $2,218 in fiscal 2026 versus a net loss of $2,676 in fiscal 2025. Basic and diluted loss per share was $0.22 in fiscal 2026 compared to $0.27 in fiscal 2025. Consolidated gross profit was $4,975 in fiscal 2026, up from $4,329 in fiscal 2025, an increase of $646 or 15%, with gross margin expanding to 16% from 13%. Operating loss improved to $1,067 in fiscal 2026 from an operating loss of $2,158 in fiscal 2025, an improvement of $1,091 or 51%. Ranor segment operating income was $3,772 in fiscal 2026 compared to $3,129 in fiscal 2025, while Stadco segment operating loss was $4,137 in fiscal 2026 compared to $4,643 in fiscal 2025. The company's provision for losses on uncompleted contracts at March 31, 2026 was $357 and at March 31, 2025 was $463 , with 95% and 88% of the totals related to customer projects at Stadco. The company had $7,031 outstanding under the Loan Agreement as of March 31, 2026.

Risk Factors

The most material risk is the substantial doubt about the company's ability to continue as a going concern, as the company was not in compliance with financial covenants in the Loan Agreement as of March 31, 2026, with $7,031 outstanding, and the lender retains the right to accelerate repayment. The company's customer concentration is a critical risk, with its four largest customers accounting for 52% of revenue in fiscal 2026 and its five largest customers accounting for 79% in fiscal 2025, and 75% of the $52,198 backlog attributable to four customers. The company's dependence on the defense industry, which generated approximately 99% of revenue in both fiscal 2026 and 2025, exposes it to reductions in U.S. defense spending and changes in government programs. The company has identified material weaknesses in internal control over financial reporting related to Stadco accounting staff insufficiency, purchase accounting, impairment accounting, and segregation of duties, which could impair its ability to produce accurate financial statements. Additionally, the company's manufacturing operations are concentrated in two facilities in Massachusetts and California, exposing it to disruption from catastrophic events.

References

  1. [1] Item 7, MD&A — Results of Operations
  2. [2] Item 7, MD&A — Results of Operations
  3. [3] Item 7, MD&A — Results of Operations
  4. [4] Item 7, MD&A — Results of Operations
  5. [5] Item 7, MD&A — Results of Operations
  6. [6] Item 7, MD&A — Results of Operations
  7. [7] Item 7, MD&A — Results of Operations
  8. [8] Item 7, MD&A — Results of Operations
  9. [9] Item 7, MD&A — Results of Operations
  10. [10] Item 7, MD&A — Results of Operations
  11. [11] Item 7, MD&A — Results of Operations
  12. [12] Item 1, Business
  13. [13] Item 1, Business
  14. [14] Item 7, MD&A — Recent Developments
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Results of Operations
  21. [21] Item 7, MD&A — Results of Operations
  22. [22] Item 7, MD&A — Results of Operations
  23. [23] Item 8, Financial Statements — Consolidated Statements of Operations
  24. [24] Item 8, Financial Statements — Consolidated Statements of Operations
  25. [25] Item 8, Financial Statements — Consolidated Statements of Operations
  26. [26] Item 8, Financial Statements — Consolidated Statements of Operations
  27. [27] Item 1, Business
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Recent Developments
  35. [35] Item 1A, Risk Factors
  36. [36] Item 1, Business
  37. [37] Item 1, Business
  38. [38] Item 1A, Risk Factors
  39. [39] Item 1, Business
  40. [40] Item 1, Business
  41. [41] Item 7, MD&A — Results of Operations
  42. [42] Item 7, MD&A — Results of Operations
  43. [43] Item 7, MD&A — Results of Operations
  44. [44] Item 8, Financial Statements — Consolidated Statements of Operations
  45. [45] Item 8, Financial Statements — Consolidated Statements of Operations
  46. [46] Item 8, Financial Statements — Consolidated Statements of Operations
  47. [47] Item 8, Financial Statements — Consolidated Statements of Operations
  48. [48] Item 7, MD&A — Results of Operations
  49. [49] Item 7, MD&A — Results of Operations
  50. [50] Item 7, MD&A — Results of Operations
  51. [51] Item 7, MD&A — Results of Operations
  52. [52] Item 7, MD&A — Results of Operations
  53. [53] Item 7, MD&A — Results of Operations
  54. [54] Item 7, MD&A — Results of Operations
  55. [55] Item 7, MD&A — Results of Operations
  56. [56] Item 7, MD&A — Results of Operations
  57. [57] Item 7, MD&A — Results of Operations
  58. [58] Item 7, MD&A — Critical Accounting Policies and Estimates
  59. [59] Item 7, MD&A — Critical Accounting Policies and Estimates
  60. [60] Item 1A, Risk Factors

Analysis on 6/25/2026